This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): peginterferon alpha-2b, Viraferonpeg, Peg-IFN, Pegintron, pegylated interferon alfa-2b, Cylatron, Sylatron

Description: PEG-Intron is a longer-acting, once-weekly pegylated version of interferon alfa-2b (INTRON A). INTRON A is a recombinant version of naturally occurring alpha interferon, which has been shown to exert both antiviral and immunomodulatory effects. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. In vitro studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Nektar supplies Advanced PEGylation reagents to Schering-Plough for use in PEG-INTRON.

In November 1990, Enzon entered into an agreement with Schering-Plough to apply its proprietary PEG technology to develop a modified form of Schering-Ploughs INTRON A. Under its licensing agreement with Schering-Plough, Schering-Plough received the worldwide rights to market PEG-INTRON, a longer-acting form of INTRON A Injection that uses proprietary PEG technology developed by Enzon. Under the Companys licensing agreement with Schering-Plough, Enzon is entitled to royalties on worldwide sales of PEG-INTRON for all indications and Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON.

In August 2007, Enzon Pharmaceuticals announced the sale of a 25% interest in its royalty from PEG-INTRON, marketed by Schering-Plough, for $92.5 million to Drug Royalty (DRI Capital). Enzon...See full deal structure in Biomedtracker

Partners: Enzon Pharmaceuticals, Inc. Nektar Therapeutics DRI Capital Inc.

Peg-Intron News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug